MedTrace Logo

An Open-Label, FIH Study Evaluating the Safety and Tolerability of VCTX210A Combination Product in Subjects With T1D

NCT05210530 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 7

Last updated 2023-06-26

No results posted yet for this study

Summary

This is an open-label, multicenter, Phase 1 study evaluating the safety and tolerability of VCTX210A combination product in patients with T1D

Conditions

Interventions

COMBINATION_PRODUCT

VCTX210A unit

CRISPR-Cas9 genetically modified PEC210A cells loaded into a delivery device

Sponsors & Collaborators

  • ViaCyte

    collaborator INDUSTRY

  • CRISPR Therapeutics AG

    lead INDUSTRY

Principal Investigators

  • Manasi Jaiman, MD, MPH · ViaCyte

  • Sandeep Soni, MD · CRISPR Therapeutics

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-24
Primary Completion
2023-01-19
Completion
2023-01-19
FDA Drug
Yes

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05210530 on ClinicalTrials.gov